FDA Approves Second CAR T-cell Therapy
- PMID: 29113977
- DOI: 10.1158/2159-8290.CD-NB2017-155
FDA Approves Second CAR T-cell Therapy
Abstract
The FDA approved the chimeric antigen receptor T-cell therapy axicabtagene ciloleucel, making it the second such treatment for blood cancers in the United States. The therapy is indicated for adults with certain non-Hodgkin lymphomas who have tried at least two other treatments.
©2018 American Association for Cancer Research.
LinkOut - more resources
Full Text Sources
Other Literature Sources